| Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy EA Reits, JW Hodge, CA Herberts, TA Groothuis, M Chakraborty, ... The Journal of experimental medicine 203 (5), 1259-1271, 2006 | 1723 | 2006 |
| Consensus guidelines for the detection of immunogenic cell death O Kepp, L Senovilla, I Vitale, E Vacchelli, S Adjemian, P Agostinis, ... Oncoimmunology 3 (9), e955691, 2014 | 842 | 2014 |
| Consensus guidelines for the definition, detection and interpretation of immunogenic cell death L Galluzzi, I Vitale, S Warren, S Adjemian, P Agostinis, AB Martinez, ... Journal for immunotherapy of cancer 8 (1), 2020 | 803 | 2020 |
| Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes CT Garnett, C Palena, M Chakarborty, KY Tsang, J Schlom, JW Hodge Cancer research 64 (21), 7985-7994, 2004 | 578 | 2004 |
| Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy M Chakraborty, SI Abrams, K Camphausen, K Liu, T Scott, CN Coleman, ... The Journal of Immunology 170 (12), 6338-6347, 2003 | 534 | 2003 |
| External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing M Chakraborty, SI Abrams, CN Coleman, K Camphausen, J Schlom, ... Cancer research 64 (12), 4328-4337, 2004 | 507 | 2004 |
| Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer JL Gulley, PM Arlen, A Bastian, S Morin, J Marte, P Beetham, KY Tsang, ... Clinical Cancer Research 11 (9), 3353-3362, 2005 | 428 | 2005 |
| Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing SR Gameiro, ML Jammed, MM Wattenberg, KY Tsang, S Ferrone, ... Oncotarget 5 (2), 403, 2014 | 414 | 2014 |
| Molecular and translational classifications of DAMPs in immunogenic cell death AD Garg, L Galluzzi, L Apetoh, T Baert, RB Birge, BS Pedro, J Manuel, ... Frontiers in immunology 6, 169354, 2015 | 394 | 2015 |
| Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach? MB Bernstein, S Krishnan, JW Hodge, JY Chang Nature reviews Clinical oncology 13 (8), 516-524, 2016 | 369 | 2016 |
| Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony … JL Marshall, JL Gulley, PM Arlen, PK Beetham, KY Tsang, R Slack, ... Journal of Clinical Oncology 23 (4), 720-731, 2005 | 354 | 2005 |
| A triad of costimulatory molecules synergize to amplify T-cell activation JW Hodge, H Sabzevari, A Gómez Yafal, L Gritz, MGO Lorenz, J Schlom Cancer research 59 (22), 5800-5807, 1999 | 354 | 1999 |
| Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ... Cancer Immunology, Immunotherapy 59, 663-674, 2010 | 344 | 2010 |
| Chemotherapy‐induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death JW Hodge, CT Garnett, B Farsaci, C Palena, KY Tsang, S Ferrone, ... International journal of cancer 133 (3), 624-636, 2013 | 295 | 2013 |
| Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer RA Madan, PM Arlen, M Mohebtash, JW Hodge, JL Gulley Expert opinion on investigational drugs 18 (7), 1001-1011, 2009 | 255 | 2009 |
| Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement CT Garnett, J Schlom, JW Hodge Clinical Cancer Research 14 (11), 3536-3544, 2008 | 250 | 2008 |
| Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma JL Gulley, PM Arlen, KY Tsang, J Yokokawa, C Palena, DJ Poole, ... Clinical Cancer Research 14 (10), 3060-3069, 2008 | 247 | 2008 |
| Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses JW Hodge, JP McLaughlin, JA Kantor, J Schlom Vaccine 15 (6-7), 759-768, 1997 | 241 | 1997 |
| Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules JW Hodge, S Abrams, J Schlom, JA Kantor Cancer Research 54 (21), 5552-5555, 1994 | 241 | 1994 |
| Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects DW Grosenbach, JC Barrientos, J Schlom, JW Hodge Cancer research 61 (11), 4497-4505, 2001 | 185 | 2001 |
